[Show abstract][Hide abstract] ABSTRACT: Chemerin is a novel adipokine that has been suggested to play an important role in the pathogenesis of the metabolic syndrome. The aim of our study was to evaluate serum chemerin as a marker of the metabolic syndrome and to assess its predictive accuracy in a Caucasian population.
The study was designed as a cross-sectional study. Anthropometric measurements and serum analyses were done for Body Mass Index, waist circumference, chemerin, insulin, triacylglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, uric acid, and glucose in 55 non-obese healthy subjects and 181 subjects at risk for the metabolic syndrome. ROC curves were determined and the Chi-squared test was used to analyse the data.
Compared with healthy controls, subjects with suspected metabolic syndrome had significantly higher chemerin serum levels (medians: 266.0 vs.192.5 microg/l; P < 0.01). After further chemerin adjustment, the difference between the subgroups persisted. Chemerin serum levels correlated with age (r = 0.23), serum glucose (r = 0.23), HDL-cholesterol (r = -0.19), triacylglycerides (r = 0.22), systolic and diastolic blood pressure (r = 0.40; r = 0.24) and the number of metabolic syndrome risk factors (r = 0.47). At a serum chemerin cut-off level of 240 microg/l, the presence of the metabolic syndrome was diagnosed with 75 % sensitivity and 67 % specificity.
In conclusion, serum chemerin levels are associated with the characteristics of the metabolic syndrome and could be an independent marker of this disorder in a Caucasian population.
Preview · Article · Dec 2008 · Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
[Show abstract][Hide abstract] ABSTRACT: Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome.
A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and 66 persons with metabolic syndrome.
Neither sex nor age influenced FGF-19 serum concentration in the healthy volunteers. Probands with metabolic syndrome had 65 % lower FGF-19 serum values than the healthy ones (medians 158.6 versus 242.4 ng/L; p<0.01). FGF-19 correlated with glucose (r = -0.35, p<0.01), HDL (r = 0.24, p = 0.045), triacylglycerols (r = -0.19, p = 0.05) and with a number of other risk factors for metabolic syndrome (r = -0.28, p = 0.01). When adjusted to the concentrations of triacylglycerols, BMI and glucose, and finally to all data pertinent to FGF-19 (according to correlation analysis), our data indicate that FGF-19 is an independent marker of metabolic syndrome.
The present study demonstrates the analytical properties of the ELISA FGF-19 assay and its usefulness when studying the metabolic syndrome. Serum concentrations of FGF-19 could be new key predictors of metabolic syndrome and thereby even a new negative risk factor of atherosclerosis.
No preview · Article · Jul 2008 · Scandinavian journal of clinical and laboratory investigation
[Show abstract][Hide abstract] ABSTRACT: Lipocalin-2 (also known as neutrophil gelatinase-associated lipocalin [NGAL]) has been described as a promising marker of metabolic syndrome associated with inflammation. The aim of our work was to develop an assay for the determination of lipocalin-2 in human serum and to investigate its levels in healthy volunteers and donors suffering from metabolic syndrome. We also conducted a pilot study on individuals with metabolic syndrome and on healthy probands and measured lipocalin-2 in these individuals. We developed and evaluated the sandwich ELISA method for the quantitative determination of human lipocalin-2 in serum samples. We measured blood pressure, waist circumference, serum cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, insulin, glucose, creatinine, hs-CRP, and adiponectin and calculated the BMI and Quicki insulin sensitivity index. In the study on 153 healthy volunteers, we showed that sex and age are not determinative for lipocalin-2 serum values. Furthermore, we tested 45 individuals with metabolic syndrome; values of lipocalin-2 did not differ (78.8 vs. 80.0 microg/l, p =0.56) from the data of healthy individuals from the first study. Neither group differed with regard to sex or age. Lipocalin-2 correlated with alanine aminotransferase (ALT) (r=-0.3, p<0.01) aspartate aminotransferase (AST) (r=-0.3, p<0.01), cholesterol (r=-0.21, p=0.047), creatinine (r=0.19, p=0.05), and high-sensitivity C-reactive protein (hs-CRP) (r=0.22, p=0.036). No significant correlation was found between serum lipocalin-2 and BMI, waist circumference, blood pressure, triglycerides, HDL, Quicki, or the number of metabolic syndrome components. When study patients with metabolic syndrome were further stratified according to the number of components of metabolic syndrome, serum concentrations of lipocalin-2 did not differ. The results presented demonstrate the analytical competence of the lipocalin-2 assay. However, we assumed that lipocalin-2 is not a routinely usable marker of metabolic syndrome or obesity. The association between serum lipocalin-2 and obesity or metabolic syndrome was not validated in our study.
No preview · Article · Jun 2008 · Hormone and Metabolic Research
[Show abstract][Hide abstract] ABSTRACT: Clusterin is a glycoprotein which participates in a number of pathophysiological processes in the organism. Information about clusterin use in the diagnosis of nephropathy and the differential diagnosis of proteinuria has been published recently.
Search for correlations between urinary clusterin concentration and other renal function markers. Evaluation of urinary clusterin measurement use in the differential diagnosis of nephropathy.
Urea, creatinine, IgG, transferin, Na, K in serum and 24-hour collected urine were measured in a sample of 82 individuals. Cystatin C in sera was also measured as were GMT, alpha-1 microglobulin, albumin, total protein in urine. In all probands urinary clusterin was assayed (ELISA).
Urinary clusterin values correlated with urinary total protein concentrations (r = 0.28; p = 0.018), total protein/creatinine index (r = 0.26; p = 0.02). No correlation was found between urine clusterin concentration and glomerular filtration rate, age, urine GMT/creatinine, alpha-1-microglobulin, urine albumin and albumin/creatinine ratio or Na, K fractional excretions. We found no urinary clusterin differences by sex of probands. No evidence of any relationship between urine clusterin and presence of defect of renal function, number of risk factors (chi(2) = 16.0; DF = 15; p = 0.38), albumin/creatinine index (chi(2) = 0.76; DF = 3; p = 0,86), total protein/creatinine (chi(2) = 6.5; DF = 3; p = 0.09), GMT/creatinine (chi(2) = 2.3; DF = 3; p = 0.51), high urinary alpha-1-microglobulin (chi(2) = 4.1; DF = 3; p = 0.25) or decreased of GFR (chi(2) = 1.3; DF = 3; p = 0.74).
A positive correlation exists between urinary clusterin and urinary total protein and total protein/ creatinine index. Urinary clusterin measurement with ELISA test does not offer any advantage over routinely used parameters for nephropathy diagnosis and the differential diagnosis of proteinuria type.
Full-text · Article · Jan 2008 · Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
[Show abstract][Hide abstract] ABSTRACT: Development, validation and clinical testing of a routine method for determination of clusterin by ELISA is presented. Clinical tests suggest using the concentration for diagnosis and monitoring of therapy of bladder cancer. The method may be also useful in diagnosis of other renal diseases. The method failed in diagnosis of asymptomatic myocardial ischemia.
[Show abstract][Hide abstract] ABSTRACT: The aim of our work was to develop an assay for the determination of proguanylin in human blood, and investigate its levels in healthy volunteers and donors suffer from hypertension often accompanied by body sodium accumulation and plasma volume expansion. We developed and evaluated the sandwich ELISA method for the quantitative determination of human proguanylin in serum samples. We conducted also the pilot study on individuals with hypertension and oh healthy probands and measured proguanylin serum levels, serum and urine sodium and creatinine levels. In the study on 256 healthy volunteers we demonstrated that women have significantly higher values of proguanylin than men (medians 12.7 vs. 9.6 ng/ml, p < 0.01) and proguanylin values increased with age of individuals (p < 0.01). Futhermore, we tested 17 individuals with hypertension and found that probands with anamnesi of hypertension had higher proguanylin values than healthy individuals from the first study (medians 16.2 vs. 11.3 ng/ml, p < 0.01). Both of groups did not differ in sex or age. Proguanylin values correlated with the systolic blood pressure (r = 0.41, p < 0.01), sodium fraction excretion (r = 0.72, p < 0.01) and serum sodium (r = -0.39, p < 0.01). No significant correlation we found with serum proguanylin and creatinine. In the group of 9 healthy probands we demonstrated the existence of a diurnal rhythm of proguanylin with its maximum in the evening hours (between 6-10 p.m.). The pilot study supports the hypothesis about the role of proguanylin in sodium metabolism and its possible importance for hypertension disorder. Further research is necessary to confirm our findings in individuals with hypertension with different medication in order to assess proguanylin value as a risk predictor of accelerated hypertension, and to classify individuals with hypertension for variuos types of diuretic therapy.
Full-text · Article · Apr 2007 · General Physiology and Biophysics
[Show abstract][Hide abstract] ABSTRACT: N1,N12-diacetylspermine, a diacetylpolyamine which was recently identified in urine, appeared to be a useful tumor marker for a number of cancers. No valid data on urine diacetylspermine concentration in patients with urinary bladder cancer exist.
Evaluation of urine N1,N12-diacetylspermine concentrations in individuals with urinary bladder cancer.
Urine samples were used from 36 patients with urothelial tumors of the urinary bladder and from 30 patients with benign urological diseases. Urine was collected before cystoscopy. Enzyme-linked immunoabsorbent assays (ELISA) were performed for diacetylspermine from urine.
Urine diacetylspermine did not differentiate in individuals with urinary bladder cancer from controls (medians 171.5 vs 143.8, p = 0.64). Its efficacy for urinary bladder cancer detection was not shown.
Urine N1,N12-diacetylspermine is probably not a useful marker for urinary bladder cancer.
Full-text · Article · Nov 2006 · Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia